Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988586 | 0.93 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29989312 | 0.93 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29988979 | 0.91 | TGM2 (1.00) | TGM2 | |
| SCHEMBL31239720 | 0.91 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29989149 | 0.91 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29989167 | 0.91 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29988824 | 0.90 | TGM2 (1.00) | TGM2 | |
| SCHEMBL31239789 | 0.90 | TGM2 (1.00) | TGM2 | |
| SCHEMBL29988786 | 0.90 | TGM2 (0.88) | TGM2 | |
| SCHEMBL29988577 | 0.87 | TGM2 (1.00) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383869-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2024-11-21 | — | — | US | disclosed |
| EP-4320106-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | University Of Ottawa (CA) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022213198-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383869-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | AADAC, NAT1, TGM2 | TGM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.